Portillo, J <br/><br/>
Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder.  [electronic resource] 

 -  Urology  Feb 1997 
 - 187-90 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0090-4295 
<br/><br/><label>Standard No.: </label>10.1016/S0090-4295(96)00455-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravesical<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Transitional Cell--prevention & control<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--prevention & control<br/>Neoplasm Staging<br/>Prospective Studies<br/>Recombinant Proteins<br/>Time Factors<br/>Urinary Bladder Neoplasms--prevention & control